Clover Biopharmaceuticals

The state of the hunt:

The European Union and India made new moves to curtail vaccine exports.
  COVAX warned of delivery delays.
  Pfizer and BioNTech launched a pediatric trial of their vaccine in children as young as 6 months.

 

Vaccines


Approved or authorized vaccines
   
New data, new questions for AstraZeneca: If AstraZeneca thought higher-than-expected efficacy results this week from the U.S.-based Phase 3 trial of AZD1222 would…

The state of the hunt:

China’s Sinovac and CNBG separately touted preliminary Phase 1/2 results for inactivated vaccine candidates—with favorable safety and immunogenicity profiles for both.
  Teams in China, Germany, Japan, South Korea, Russia and the United Kingdom are set to begin first-in-human clinical trials for six different investigational vaccines.
  Commonly available steroid dexamethasone reduced mortality in Covid-19 patients requiring respiratory support, an…


The state of the hunt: 

Chinese developers now have three vaccine candidates in clinical trials. Gilead’s antiviral remdesivir looked anecdotally more promising this week after STAT reported favorable patient outcomes in a Chicago hospital involved in its Phase 3 trials. STAT Further bolstering remdesivir, the U.S. National Institutes of Health issued a press release today touting a preprint government study that found the drug “reduced clinical disease” and lung damage in rhesus…

As the United States eclipsed China in confirmed cases, more vaccines neared human trials and funders made over $330 million in new commitments to fight Covid-19.

The week’s noteworthy developments included:

Vaccines

On vaccines, the University of Oxford announced today that it has begun recruiting volunteers for clinical trials—set to begin in weeks—of ChAdOx1 nCov-19, its adenovirus vector-based shot.

Sanofi announced today a collaboration with Massachusetts…